INTS
INTENSITY THERAPEUTICS, INC.

2,330
Mkt Cap
$15.15M
Volume
48,434.00
52W High
$54.50
52W Low
$4.63
PE Ratio
-0.38
INTS Fundamentals
Price
$5.98
Prev Close
$6.33
Open
$6.28
50D MA
$8.32
Beta
0.00
Avg. Volume
88,259.24
EPS (Annual)
-$29.24
P/B
1.63
Rev/Employee
$0.00
$22.02
Loading...
Loading...
News
all
press releases
Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study
Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical...
PR Newswire·9d ago
News Placeholder
More News
News Placeholder
Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement
Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement PR Newswire SHELTON, Conn...
PR Newswire·15d ago
News Placeholder
Why Did INTS Stock Plummet 25% Today?
Intensity Therapeutics announced a 1-for-25 reverse stock split, consolidating every 25 existing shares into a single new share.
Stocktwits·1mo ago
News Placeholder
Intensity Therapeutics Announces Reverse Stock Split
Intensity Therapeutics Announces Reverse Stock Split Intensity Therapeutics Announces Reverse Stock Split PR Newswire SHELTON, Conn., Feb. 13, 2026 Intensity's common stock is expected to begin...
PR Newswire·1mo ago
News Placeholder
Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities
Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities PR Newswire SHELTON...
PR Newswire·2mo ago
News Placeholder
All You Need to Know About Intensity Therapeutics Inc. (INTS) Rating Upgrade to Buy
Intensity Therapeutics Inc. (INTS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·3mo ago
News Placeholder
Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium
Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium...
PR Newswire·3mo ago
News Placeholder
Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement
Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's...
PR Newswire·4mo ago
News Placeholder
Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium
Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast...
PR Newswire·4mo ago
News Placeholder
Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update PR...
PR Newswire·5mo ago
<
1
2
...
>

Latest INTS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.